| Fri, 09 Apr 2021 12:46:36: | Life sciences pumping more cash than ever into R&D, but drug pricing limits could stymie that tide: report
|
| Fri, 09 Apr 2021 11:29:03: | Chutes & Ladders—3 weeks after leaving bluebird, CMO Davidson lands at Tessera
|
| Fri, 09 Apr 2021 09:57:32: | Sanofi drops 'intriguing' data on rival to Bristol Myers' bempeg
|
| Fri, 09 Apr 2021 09:51:00: | Provention warns FDA requests could delay diabetes approval
|
| Fri, 09 Apr 2021 07:26:55: | Werewolf Therapeutics looks to make a killing in the public markets with a $100M IPO
|
| Thu, 08 Apr 2021 12:48:14: | MIT and UCSF researchers create CRISPR ‘on-off switch’ that controls gene expression without changing DNA
|
| Thu, 08 Apr 2021 12:17:33: | Bannister joins SVB to help companies raise cash, access public markets
|
| Thu, 08 Apr 2021 10:13:52: | Lilly, AbCellera tout COVID-19 antibody combo potential as it loses strength against variants
|
| Thu, 08 Apr 2021 08:40:36: | CytoDyn's chief scientific officer Rahman quietly exits amid leronlimab limbo
|
| Thu, 08 Apr 2021 06:13:46: | Ventus raises $100M to pursue NLRP3, crack undruggable targets
|
| Wed, 07 Apr 2021 13:07:06: | Bayer-backed Metagenomi bumps up series A to $75M as it gears up for gene editing push
|
| Wed, 07 Apr 2021 12:22:36: | Icosavax raises $100M to take RSV, COVID-19 vaccines into clinic
|
| Wed, 07 Apr 2021 11:05:31: | Bluebird's chief medical officer flies the nest to gene writing biotech Tessera
|
| Tue, 06 Apr 2021 16:02:51: | Novartis taps Artios for targets to enhance radioligand drugs
|
| Tue, 06 Apr 2021 14:15:10: | 'Unsurprising' but 'deeply disappointing': Deerfield report finds vast gender gap in VC-backed healthcare
|
| Tue, 06 Apr 2021 12:09:12: | Scholar Rock eyes phase 3 after confirming effects of SMA drug
|
| Tue, 06 Apr 2021 10:07:13: | Novavax adds blinded crossover arms to COVID-19 vaccine trials
|
| Mon, 05 Apr 2021 13:02:42: | Pfizer's Vizimpro is among 3 FDA-approved drugs that combat COVID-19 in lung cells: report
|
| Mon, 05 Apr 2021 12:21:57: | Watchdog calls for probe into 'inappropriate' FDA-Biogen aducanumab collaboration
|
| Mon, 05 Apr 2021 12:00:14: | Iveric Bio's executive chair, founder Guyer steps down, rejoins SV Health Investors
|
| Mon, 05 Apr 2021 11:45:02: | Takeda, CSL pandemic plasma therapy fails phase 3, as COVID Alliance axed
|
| Mon, 05 Apr 2021 10:39:11: | Legend Biotech, J&J finish off rolling submission for CAR-T hopeful, approach finish line
|
| Fri, 02 Apr 2021 12:43:31: | Alloy Therapeutics nabs a $75M series C to sow more seeds into the biotech ecosystem
|
| Fri, 02 Apr 2021 12:30:11: | Chutes & Ladders—With Liang set to retire, BeiGene names new chief financial officer
|
| Fri, 02 Apr 2021 10:13:00: | Merck KGaA lands rights to 3rd F-star oncology bispecific antibody
|
